Denali Therapeutics Inc (NASDAQ: DNLI) is -7.83% lower on its value in year-to-date trading and has touched a low of $15.45 and a high of $33.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DNLI stock was last observed hovering at around $20.21 in the last trading session, with the day’s loss setting it -0.43%.
Currently trading at $19.78, the stock is 13.26% and 5.67% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.41 million and changing -2.13% at the moment leaves the stock -14.02% off its SMA200. DNLI registered -27.15% loss for a year compared to 6-month loss of -13.78%. The firm has a 50-day simple moving average (SMA 50) of $5.29 and a 200-day simple moving average (SMA200) of -$9.72.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 18.37% gain in the last 1 month and extending the period to 3 months gives it a 7.97%, and is 17.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.33% over the week and 6.36% over the month.
Denali Therapeutics Inc (DNLI) has around 445 employees, a market worth around $2.73B and $330.53M in sales. Profit margin for the company is -43.94%. Distance from 52-week low is 28.03% and -40.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.50%).
Denali Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.78 with sales reaching $12.68M over the same period.The EPS is expected to shrink by -151.46% this year, but quarterly earnings will post -77.70% year-over-year. Quarterly sales are estimated to shrink -63.90% in year-over-year returns.
313 institutions hold shares in Denali Therapeutics Inc (DNLI), with institutional investors hold 95.54% of the company’s shares. The shares outstanding are 138.39M, and float is at 111.20M with Short Float at 9.73%. Institutions hold 81.89% of the Float.
The top institutional shareholder in the company is Baillie Gifford and Company with over 14.84 million shares valued at $438.04 million. The investor’s holdings represent 10.80% of the DNLI Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 10.24 million shares valued at $302.27 million to account for 7.45% of the shares outstanding. The other top investors are Blackrock Inc. which holds 10.11 million shares representing 7.36% and valued at over $298.24 million, while Wellington Management Group, LLP holds 5.12% of the shares totaling 7.04 million with a market value of $207.7 million.
Denali Therapeutics Inc (DNLI) Insider Activity
A total of 4 insider transactions have happened at Denali Therapeutics Inc (DNLI) in the last six months, with sales accounting for 4 and purchases happening 0 times. The most recent transaction is an insider sale by SATO VICKI L, the company’s Director. SEC filings show that SATO VICKI L sold 1,666 shares of the company’s common stock on Feb 15 at a price of $18.37 per share for a total of $30604.0. Following the sale, the insider now owns 0.12 million shares.
Denali Therapeutics Inc disclosed in a document filed with the SEC on Feb 14 that Schuth Alexander O. (COFO and Secretary) sold a total of 20,128 shares of the company’s common stock. The trade occurred on Feb 14 and was made at $17.66 per share for $0.36 million. Following the transaction, the insider now directly holds 0.19 million shares of the DNLI stock.
Still, SEC filings show that on Feb 14, Ho Carole (Chief Medical Officer) disposed off 1,405 shares at an average price of $17.79 for $24995.0. The insider now directly holds 143,605 shares of Denali Therapeutics Inc (DNLI).
Denali Therapeutics Inc (DNLI): Who are the competitors?
One of the company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -88.69% down over the past 12 months.Plandai Biotechnology Inc. (PLPL) lies in the list of competitors of the Denali Therapeutics Inc and is -33.33% lower over the same period from DNLI
